99mTc-EDDA/HYNIC-TOC in the management of medullary thyroid carcinoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 2, 2004, Pages 211-217

  Parisella, Maria ^a   D'Alessandria, Calogero ^a   Van De Bossche, Bieke ^b   Chianelli, Marco ^c   Ronga, Giuseppe ^a   Papini, Enrico ^c   Mikolajczak, Renata ^d   Letizia, Claudio ^a   De Toma, Giorgio ^a   Veneziani, Augusto ^e   Scopinaro, Francesco ^a   Signore, Alberto ^a,f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b GHENT UNIVERSITY   (Belgium)

^c REGINA APOSTOLORUM HOSPITAL   (Italy)

^d SOLTAN INSTITUTE FOR NUCLEAR STUDIES   (Poland)

^e CATHOLIC UNIVERSITY   (Italy)

^f POLICLINICO UMBERTO I   (Italy)

Author keywords

Medullary thyroid carcinoma; Scintigraphy; Somatostatin receptors

Indexed keywords

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; ETHYLENEDIAMINE DERIVATIVE; FLUORODEOXYGLUCOSE F 18; NICOTINAMIDE DERIVATIVE; OCTREOTIDE[3 TYROSINE]; OCTREOTIDE[3 TYROSINE] ETHYLENEDIAMINEDIACETIC ACID HYDRAZINONICOTINAMIDE TC 99M; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SUCCIMER TC 99M; TECHNETIUM 99M; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; TECHNETIUM 99M EDDA HYNIC TYR(3) OCTREOTIDE; TECHNETIUM 99M EDDA-HYNIC-TYR(3)-OCTREOTIDE; TECHNETIUM COMPLEX;

ADULT; AGED; CANCER LOCALIZATION; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DRUG CLEARANCE; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; SIDE EFFECT; THYROID MEDULLARY CARCINOMA; ARTICLE; COMPARATIVE STUDY; MEDULLARY CARCINOMA; MIDDLE AGED; THYROID TUMOR;

AGED; CARCINOMA, MEDULLARY; HUMANS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; THYROID NEOPLASMS;

EID: 16544370349     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497804323071995     Document Type: Conference Paper

References (28)

1. Sipple JH. The association of pheocromocitoma with carcinoma of the thyroid gland. Am J Med 1961;31:163.
2. Kebebew E, Ituarte PHG, Siperstein AE, et al. Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000;88:1139.
3. Kallinowski F, Buhr HJ, Meybie H, et al. Medullary carcinoma of the thyroid: Therapeutic strategy derived from fifteen years of experience. Surgery 1993;114:491.
4. Moley JF, De Benedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: Recommendations for extent of node dissection. Ann Surg 1999;229:880.
5. Abdelmoumene N, Sclumberger M, Gardet P, et al. Selective venous sampling catheterization for localization of persisting medullary carcinoma. Br J Cancer 1994;69:1141.
6. Baulieu JL, Guilloteau D, Delisle MJ, et al. Radioiodinated metaiodonenzylguanidine uptake in medullary thyroid cancer: A French cooperative study. Cancer 1987;60:2189.
7. Arnstein NB, Juni JE, Sisson JC, et al. Recurrent thyroid carcinoma of the thyroid demonstrated by thallium-201 scintigraphy. J Nucl Med 1986;27:1564.
8. Baudin E, Lumbroso J, Schlumberger M, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996;37:912.
9. Manil L, Boudet F, Motte P, et al. Positive anticalcitonin immunoscintigraphy in patients with medullary thyroid carcinoma and small lung cancer. Cancer Res 1989;49:5480.
10. Behr TM, Gratz S, Markus PM, et al. Anticarcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma. Cancer 1997;80:2436.
11. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002;43:66.
12. 18F-DOPA positron emission tomography for tumor detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001;28:64.
13. Chen H, Roberts JR, Ball DW, et al. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg 1997;59:279.
14. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273.
15. De Jong M, Kwekkeboom D, Valkema R, et al. Radiolabeled peptides for tumor therapy: Current status and future directions Plenary lecture at the EANM 2002. Eur J Nucl Mol Imaging 2003;30:463.
16. 99mTc-somatostatin analogues effect of labeling methods and peptide sequence. Eur J Nucl Med 1999;26:869.
17. 111In-octreotide. J Nucl Med 2000;41:1114.
18. 111In-labeled octreotide derivates. Eur J Nucl Med 2000;27:1318.
19. Schewerk WB, Grun R, Wahl R. Ultrasound diagnosis of C-cell carcinoma of the thyroid. Cancer 1985;55:624.
20. Wang Q, Takashima S, Fukuda H, et al. Detection of medullary thyroid carcinoma and regional lymph node metastases by magnetic resonance imaging. Arch Otolaryngol Head Neck Surg 1999;125:842.
21. Diehl M, Risse JH, Brandt-Mainz K, et al. Flourine-18-flourodeoxyglucose positron emission tomography in medullary thyroid cancer: Results of a multicentre study. Eur J Nucl Med 2001;28:1671.
22. Krauz Y, Rosler A, Guttman H, et al. Somatostatin receptor scintigraphy of regional and distant metastases of medullary thyroid carcinoma in the thyroid. Clin Nucl Med 1999;4:256.
23. Adams S, Baum RP, Hertel A, et al. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 1998;25:1277.
24. 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur J Nucl Med 1996;23:1367.
25. Strauss LG, Conti PS. The application of PET in clinical oncology. J Nucl Med 1991;32:623.
26. Gasparoni P, Rubello D, Ferlin G. Potential role of flourine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of the primitive and recurrent medullary thyroid carcinoma. J Endocrinol Inv 1997;20:527.
27. Lambert SWJ, Krenning E, Reubi JC. The role of the somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrinol Rev 1991;12:450.
28. Breeman WAP, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: Basic science, current knowledge, limitations, and future perspectives. Eur J Nucl Med 2001;28:1421.